National Institutes of Health-Pharmaceuticals & Healthcare-Deals and Alliances Profile

National Institutes of Health-Pharmaceuticals & Healthcare-Deals and Alliances Profile


  • Products Id :- GDPH81561D
  • |
  • Pages: 534
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

National Institutes of Health (NIH) a subsidiary of U.S. Department of Health and Human Services is a medical research institute that discovers and develops research strategies for the improvement of health. The institute's medical research initiatives includes environmental influence on the child health outcomes, NIH common fund, data science at NIH, precision medicine initiative cohort program, the brain initiative, and others. It also offers training and education program in intramural, extramural and clinical research training for medical education. The institute operates through centers with an expertise in diseases and body systems. NIH is headquartered in Bethesda, Maryland, the US.

National Institutes of Health-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 12

List of Figures 16

National Institutes of Health, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 17

National Institutes of Health, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 18

National Institutes of Health, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 19

National Institutes of Health, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 20

National Institutes of Health, Medical Devices Deals, 2011 to YTD 2017 22

National Institutes of Health, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 23

National Institutes of Health, Pharmaceuticals & Healthcare, Deal Details 34

Venture Financing 34

Aura Biosciences Secures An Additional US$3 Million In Series A Financing 34

Partnerships 34

ConverGene Enters into Development Agreement with National Institute of Neurological Disorders and Stroke 34

Oncoceutics Enters into Research Agreement with National Institutes of Health 35

Cyprium Therapeutics Enters into Research and Development Agreement with Eunice Kennedy Shriver NICHD 36

Achieve Life Science and OncoGenex Pharma Enter into Partnership with National Institutes of Health 37

Geneuro Enters into Agreement with National Institute of Neurological Disorders and Stroke 38

Chrysalis BioTherapeutics Enters into Agreement with National Institute of Allergy and Infectious Diseases 38

Agenus Enters into Agreement with National Cancer Institute 39

Threshold Pharma Enters into Agreement with National Cancer Institute 40

Syndax Pharma Enters into Co-Development Agreement with National Cancer Institute 41

Immunovia to Enter into Agreement with National Cancer Institute 42

Pfizer Enters into Agreement with National Cancer Institute 42

Epizyme Enters into Research Agreement with National Cancer Institute 43

Human Metabolome Technologies Enters into Agreement with National Institute on Aging 44

Atrin Pharma Enters into Agreement with National Cancer Institute 45

Riptide Bioscience Enters into Agreement with National Cancer Institute 46

PapGene Enters into Agreement with National Cancer Institute 46

Cellerant Therapeutics Enters into Contract with National Institutes of Health 47

Cellectar Biosciences Enters into Contract with National Cancer Institute 48

University of Pittsburgh Cancer Institute Enters into Contract with National Cancer Institute 48

Advanced Accelerator Applications Enters into Agreement with National Cancer Institute 49

Evolva Enters into Agreement with National Institute of Allergy and Infectious Diseases 50

RedHill Biopharma Enters into Agreement with NIAID 51

Agilis Biotherapeutics Partners with National Center for Accelerating Translational Sciences 52

Cellular Dynamics International Enters into R&D Agreement with National Eye Institute 52

Kite Pharma Enters into R&D Agreement with National Cancer Institute 53

Inovio Pharma Partners with National Cancer Institute and Mayo Clinic 54

Altor BioScience Enters into Co-Development Agreement with National Cancer Institute 55

NantBioScience and NantKwest Enters into R&D Agreement with National Cancer Institute 56

Eagle Pharma Enters into Agreement with National Institutes of Health 57

Asterand Bioscience Enters into Contract Agreement with National Institutes of Health 57

PDS Biotechnology Enters into R&D Agreement with National Cancer Institute 58

New England Research Institutes Enters into Research Agreement with National Heart Lung and Blood Institute 59

Regen BioPharma Enters into Research Agreement with National Institutes of Health 60

RespireRx Pharma Enters into Research Agreement with National Institute of Drug Abuse 60

OriGene Technologies Enters into Contract with National Cancer Institute 61

SolaranRx Enters into R&D Agreement with National Cancer Institute 62

Kite Pharma Enters into Research and Development Agreement with National Cancer Institute 63

Precision Biologics Enters into R&D Agreement with National Cancer Institute 64

Cancer Targeted Technology Enters into Contract Agreement with National Cancer Institute 65

GlaxoSmithKline Enters into Research Agreement with NIAID 66

Cerulean Pharma and AstraZeneca Enter into Research Agreement with National Cancer Institute 66

PepTcell Enters into Research and Development Agreement National Institute of Allergy and Infectious Diseases 67

Saint Louis University Enters into Agreement with National Institutes of Health 68

SRI International Enters into Biological Testing Facility Contract with NICHD 69

KIYATEC Enters into Research Contract with National Cancer Institute 70

Protein Foundry Enters into Research Contract with NHLBI 70

SuviCa Enters into Contract with National Cancer Institute 71

SRI International Enters into Agreement with National Institute of Allergy and Infectious Diseases 72

Galena Biopharma Enters into Agreement with National Cancer Institute 73

WiCell Research Institute Enters into Distribution Agreement with NHLBI 74

Etubics Enters into R&D Agreement with National Cancer Institute 74

Thrombolytic Science Enters into Agreement with National Institute of Neurological Disorders and Stroke 75

GenSight Biologics Enters into Research Agreement with Pierre and Marie Curie University, INSERM and CNRS 76

FirstString Research Enters into R&D Agreement with NCATS 77

Zydus Cadila Healthcare Enters into Research Agreement with National Institute of Allergy and Infectious Diseases 78

GenVec Enters into Research Agreement with LMIV 78

GeoVax Labs Enters into Research Agreement with National Institute of Allergy and Infectious Diseases 79

BioAegis Therapeutics Enters into Research Agreement with the National Institute of Allergy and Infectious Disease 80

Intrexon Enters into R&D Agreement with National Cancer Institute 81

Emergent BioSolutions Signs Agreement with Oxford University, GlaxoSmithKline and NIAID for the Production of an MVA Ebola Zaire Vaccine Candidate 82

Kite Pharma Amends R&D Agreement with National Cancer Institute for Cancer Immunotherapy Products 83

VistaGen Therapeutics Enters into R&D Agreement with National Institute of Mental Health 84

Lion Biotech Amends Co-Development Agreement with National Cancer Institute 85

MedImmune Enters into Co-Development Agreement with National Cancer Institute 86

Vtesse Enters into Agreement with National Institutes of Health for VTS-270 86

ArQule Enters into Co-Development Agreement with National Human Genome Research Institute for ARQ 092 87

GenSight Biologics Enters into Research Agreement with UPMC, INSERM and CNRS 88

Kadmon Enters into R&D Agreement with NIDCR 89

Foamix Enters into Co-Development Agreement with National Eye Institute 90

New Amsterdam Sciences to Enter into Research Agreement with National Institute of Health 91

Paradigm Shift Therapeutics Enters into Agreement with National Cancer Institute 91

Organovo Enters Into Co-Development Agreement With National Center For Advancing Translational Sciences And National Institutes of Health 92

Lightlake Therapeutics Expands Co-Developmenet Agreement With National Institute On Drug Abuse 93

Nanobiotix Enters Into Co-Development Agreement With National Cancer Institute For NBTX-IV 94

Lightlake Therapeutics Enters Into Co-Development Agreement With National Institute On Drug Abuse 95

National Cancer Institute Enters Into Co-Development Agreement With Seoul National University Hospital For Proteomic Technologies 96

Kite Pharma Enters Into R&D Agreement With National Cancer Institute For Cellular Immunotherapy Products 97

Diurnal Extends Cooperative Research and Development Agreement with National Institutes of Health 98

DFH Pharma Enters Into Co-Development Agreement With NIAID For HIV Maturation Inhibitor Drugs 98

Rockland Immunochemicals Enters Into Co-Development Agreement With National Cancer Institute 99

ImmunoVaccine Enters into Research Agreement with National Institute of Allergy and Infectious Diseases 100

Delcath Systems Extends Co-Development Agreement With National Cancer Institute 101

FEI Enters Into R&D Agreement With NIH 102

DFH Pharma Enters Into Co-Development Agreement With National Cancer Institute 103

Raptor Pharma Enters Into Co-Development Agreement With NIDDK For RP104 104

Concert Pharma Enters Into Research Agreement With NIH 105

AVI BioPharma Enters Into Co-Development Agreement With National Institutes of Health For Exon 50 106

BN ImmunoTherapeutics Expands Co-Development Agreement With National Cancer Institute 107

Afraxis Enters Into Co-Development Agreement With National Institutes of Health 108

Aura Biosciences Enters Into Research And Development Agreement With NIH 109

Genesis Biopharma Enters Into Co-Development Agreement With The National Cancer Institute 110

Pharmacyclics Enters Into Co-Development Agreement With National Cancer Institute For PCI-32765 111

Viamet Pharma Enters Into Co-Development Agreement With National Institutes of Health 112

GNS Healthcare Enters Into An Agreement With National Cancer Institute 113

Amsterdam Molecular Enters Into Cooperative Research and Development Agreement With National Institutes of Health 114

New Zealand Pharma Enters Into Co-Development Agreement With National Human Genome Research Institute For DEX-M74 115

RRD International Enters Into Co-Development Agreement With National Institutes of Health Therapeutics For Rare And Neglected Diseases 116

Licensing Agreements 117

Selecta Biosciences Enters into Licensing Agreement with National Cancer Institute 117

NICHD Enters into Licensing Agreement with Cyprium Therapeutics 118

PaxVax Enters into Licensing Agreement with National Institutes of Health 119

ConverGene Enters into Licensing Agreement with National Center for Advancing Translational Sciences 120

Great Lakes Neuroscience Enters into Licensing Agreement with National Institutes of Health 120

Genesis Biopharma Enters Into Patent Licensing Agreement With National Institutes Of Health 121

Biologics Resources Enters into Licensing Agreement with National Institutes of Health 122

Medigen Vaccine Biologics Enters into Licensing Agreement with National Institutes of Health for Dengue Vaccine 123

Opiant Pharma Enters into Licensing Agreement with Walter Reed Army Institute of Research and National Institute on Drug Abuse 124

Kite Pharma Enters into Licensing Agreement with National Institutes of Health 125

Kite Pharma Enters into Licensing Agreement with National Institutes of Health 125

Butantan Institute Enters into Licensing Agreement with National Institute of Allergy and Infectious Diseases 126

Kite Pharma Enters into Licensing Agreement with National Institutes of Health 127

Lion Biotech Enters into Licensing Agreement with National Institutes of Health 128

Vtesse Enters into Licensing Agreement with National Institutes of Health for Cyclodextrins 129

Kite Pharma Enters into Licensing Agreement with National Institutes of Health for T Cell Receptor-Based Products 129

Exxell BIO Enters into Licensing Agreement with National Institute of Allergy and Infectious Diseases 131

Peptron Enters into Licensing agreement with National Institutes of Health 131

KannaLife Sciences Enters Into Licensing Agreement With NIH 132

Organic Vaccines Enters into Licensing Agreement with National Institutes of Health 133

Kite Pharma Enters into Licensing Agreement with National Institutes of Health for T Cell Receptor-Based Products 133

Aspyrian Therapeutics Enters Into Licensing Agreement With National Cancer Institute For Near-Infrared Photoimmunotherapy 134

Polyplus-transfection Enters into Licensing Agreeement with NIAID and NCI 135

Bavarian Nordic Enters into Licensing Agreement with National Institutes of Health 136

Radiation Control Technologies Enters Into Licensing Agreement With National Institutes of Health 137

NIH Center for Regenerative Medicine Enters Into Licensing Agreement With Horizon Discovery For Genesis Technology 137

KannaLife Sciences Enters Into Licensing Agreement With NIH-OTT 138

BioDigitalValley Enters Into Licensing Agreement With National Library of Medicine 139

BN ImmunoTherapeutics Enters Into Licensing Agreement With National Institutes of Health 139

Amsterdam Molecular Expands Licensing Agreement With National Institutes Of Health 141

NanoBio Enters Into Licensing Agreement With National Institutes Of Health 141

Ariadne Genomics Extends Licensing Agreement With NCI For Pathway Studio 142

National Institutes of Health - Key Competitors 144

Key Employees 145

Locations And Subsidiaries 146

Head Office 146

Other Locations & Subsidiaries 146

Recent Developments 152

Corporate Communications 152

Apr 25, 2016: Dr. Laura Forese Appointed Chairperson Of NIH Clinical Center Hospital Board 152

Legal and Regulatory 153

Jan 11, 2017: New Drug Formulary Will Help Expedite Use of Agents in Clinical Trials 153

Mar 22, 2016: Geisinger Health System receives accreditation from the Association for the Accreditation of Human Research Protection Programs 154

Government and Public Interest 155

May 04, 2017: Global Alzheimer's Platform Foundation Supports $400 Million Congressional Increase for Alzheimer's Research Funding 155

May 03, 2017: Center for AIDS Research Receives $15.5 Million Grant from NIH 156

May 02, 2017: NIH discovery in mice could lead to new class of medications to fight mid-life obesity 157

Apr 30, 2017: UNC wins competitive NIH grant to study how nicotine affects lungs 158

Apr 27, 2017: Antidepressant may enhance drug delivery to the brain 159

Apr 21, 2017: NIH Funds Seven International Centers of Excellence for Malaria Research 160

Apr 18, 2017: Researchers discover mitochondrial circuit breaker that protects heart from damage 162

List of Figures

National Institutes of Health, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1

National Institutes of Health, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1

National Institutes of Health, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1

National Institutes of Health, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1

National Institutes of Health, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 17

National Institutes of Health, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 18

National Institutes of Health, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 19

National Institutes of Health, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 20

National Institutes of Health, Medical Devices Deals, 2011 to YTD 2017 22

List of Tables

National Institutes of Health, Pharmaceuticals & Healthcare, Key Facts 1

National Institutes of Health, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 17

National Institutes of Health, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 18

National Institutes of Health, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 19

National Institutes of Health, Deals By Therapy Area, 2011 to YTD 2017 20

National Institutes of Health, Medical Devices Deals, 2011 to YTD 2017 22

National Institutes of Health, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 23

Aura Biosciences Secures An Additional US$3 Million In Series A Financing 34

ConverGene Enters into Development Agreement with National Institute of Neurological Disorders and Stroke 34

Oncoceutics Enters into Research Agreement with National Institutes of Health 35

Cyprium Therapeutics Enters into Research and Development Agreement with Eunice Kennedy Shriver NICHD 36

Achieve Life Science and OncoGenex Pharma Enter into Partnership with National Institutes of Health 37

Geneuro Enters into Agreement with National Institute of Neurological Disorders and Stroke 38

Chrysalis BioTherapeutics Enters into Agreement with National Institute of Allergy and Infectious Diseases 38

Agenus Enters into Agreement with National Cancer Institute 39

Threshold Pharma Enters into Agreement with National Cancer Institute 40

Syndax Pharma Enters into Co-Development Agreement with National Cancer Institute 41

Immunovia to Enter into Agreement with National Cancer Institute 42

Pfizer Enters into Agreement with National Cancer Institute 42

Epizyme Enters into Research Agreement with National Cancer Institute 43

Human Metabolome Technologies Enters into Agreement with National Institute on Aging 44

Atrin Pharma Enters into Agreement with National Cancer Institute 45

Riptide Bioscience Enters into Agreement with National Cancer Institute 46

PapGene Enters into Agreement with National Cancer Institute 46

Cellerant Therapeutics Enters into Contract with National Institutes of Health 47

Cellectar Biosciences Enters into Contract with National Cancer Institute 48

University of Pittsburgh Cancer Institute Enters into Contract with National Cancer Institute 48

Advanced Accelerator Applications Enters into Agreement with National Cancer Institute 49

Evolva Enters into Agreement with National Institute of Allergy and Infectious Diseases 50

RedHill Biopharma Enters into Agreement with NIAID 51

Agilis Biotherapeutics Partners with National Center for Accelerating Translational Sciences 52

Cellular Dynamics International Enters into R&D Agreement with National Eye Institute 52

Kite Pharma Enters into R&D Agreement with National Cancer Institute 53

Inovio Pharma Partners with National Cancer Institute and Mayo Clinic 54

Altor BioScience Enters into Co-Development Agreement with National Cancer Institute 55

NantBioScience and NantKwest Enters into R&D Agreement with National Cancer Institute 56

Eagle Pharma Enters into Agreement with National Institutes of Health 57

Asterand Bioscience Enters into Contract Agreement with National Institutes of Health 57

PDS Biotechnology Enters into R&D Agreement with National Cancer Institute 58

New England Research Institutes Enters into Research Agreement with National Heart Lung and Blood Institute 59

Regen BioPharma Enters into Research Agreement with National Institutes of Health 60

RespireRx Pharma Enters into Research Agreement with National Institute of Drug Abuse 60

OriGene Technologies Enters into Contract with National Cancer Institute 61

SolaranRx Enters into R&D Agreement with National Cancer Institute 62

Kite Pharma Enters into Research and Development Agreement with National Cancer Institute 63

Precision Biologics Enters into R&D Agreement with National Cancer Institute 64

Cancer Targeted Technology Enters into Contract Agreement with National Cancer Institute 65

GlaxoSmithKline Enters into Research Agreement with NIAID 66

Cerulean Pharma and AstraZeneca Enter into Research Agreement with National Cancer Institute 66

PepTcell Enters into Research and Development Agreement National Institute of Allergy and Infectious Diseases 67

Saint Louis University Enters into Agreement with National Institutes of Health 68

SRI International Enters into Biological Testing Facility Contract with NICHD 69

KIYATEC Enters into Research Contract with National Cancer Institute 70

Protein Foundry Enters into Research Contract with NHLBI 70

SuviCa Enters into Contract with National Cancer Institute 71

SRI International Enters into Agreement with National Institute of Allergy and Infectious Diseases 72

Galena Biopharma Enters into Agreement with National Cancer Institute 73

WiCell Research Institute Enters into Distribution Agreement with NHLBI 74

Etubics Enters into R&D Agreement with National Cancer Institute 74

Thrombolytic Science Enters into Agreement with National Institute of Neurological Disorders and Stroke 75

GenSight Biologics Enters into Research Agreement with Pierre and Marie Curie University, INSERM and CNRS 76

FirstString Research Enters into R&D Agreement with NCATS 77

Zydus Cadila Healthcare Enters into Research Agreement with National Institute of Allergy and Infectious Diseases 78

GenVec Enters into Research Agreement with LMIV 78

GeoVax Labs Enters into Research Agreement with National Institute of Allergy and Infectious Diseases 79

BioAegis Therapeutics Enters into Research Agreement with the National Institute of Allergy and Infectious Disease 80

Intrexon Enters into R&D Agreement with National Cancer Institute 81

Emergent BioSolutions Signs Agreement with Oxford University, GlaxoSmithKline and NIAID for the Production of an MVA Ebola Zaire Vaccine Candidate 82

Kite Pharma Amends R&D Agreement with National Cancer Institute for Cancer Immunotherapy Products 83

VistaGen Therapeutics Enters into R&D Agreement with National Institute of Mental Health 84

Lion Biotech Amends Co-Development Agreement with National Cancer Institute 85

MedImmune Enters into Co-Development Agreement with National Cancer Institute 86

Vtesse Enters into Agreement with National Institutes of Health for VTS-270 86

ArQule Enters into Co-Development Agreement with National Human Genome Research Institute for ARQ 092 87

GenSight Biologics Enters into Research Agreement with UPMC, INSERM and CNRS 88

Kadmon Enters into R&D Agreement with NIDCR 89

Foamix Enters into Co-Development Agreement with National Eye Institute 90

New Amsterdam Sciences to Enter into Research Agreement with National Institute of Health 91

Paradigm Shift Therapeutics Enters into Agreement with National Cancer Institute 91

Organovo Enters Into Co-Development Agreement With National Center For Advancing Translational Sciences And National Institutes of Health 92

Lightlake Therapeutics Expands Co-Developmenet Agreement With National Institute On Drug Abuse 93

Nanobiotix Enters Into Co-Development Agreement With National Cancer Institute For NBTX-IV 94

Lightlake Therapeutics Enters Into Co-Development Agreement With National Institute On Drug Abuse 95

National Cancer Institute Enters Into Co-Development Agreement With Seoul National University Hospital For Proteomic Technologies 96

Kite Pharma Enters Into R&D Agreement With National Cancer Institute For Cellular Immunotherapy Products 97

Diurnal Extends Cooperative Research and Development Agreement with National Institutes of Health 98

DFH Pharma Enters Into Co-Development Agreement With NIAID For HIV Maturation Inhibitor Drugs 98

Rockland Immunochemicals Enters Into Co-Development Agreement With National Cancer Institute 99

ImmunoVaccine Enters into Research Agreement with National Institute of Allergy and Infectious Diseases 100

Delcath Systems Extends Co-Development Agreement With National Cancer Institute 101

FEI Enters Into R&D Agreement With NIH 102

DFH Pharma Enters Into Co-Development Agreement With National Cancer Institute 103

Raptor Pharma Enters Into Co-Development Agreement With NIDDK For RP104 104

Concert Pharma Enters Into Research Agreement With NIH 105

AVI BioPharma Enters Into Co-Development Agreement With National Institutes of Health For Exon 50 106

BN ImmunoTherapeutics Expands Co-Development Agreement With National Cancer Institute 107

Afraxis Enters Into Co-Development Agreement With National Institutes of Health 108

Aura Biosciences Enters Into Research And Development Agreement With NIH 109

Genesis Biopharma Enters Into Co-Development Agreement With The National Cancer Institute 110

Pharmacyclics Enters Into Co-Development Agreement With National Cancer Institute For PCI-32765 111

Viamet Pharma Enters Into Co-Development Agreement With National Institutes of Health 112

GNS Healthcare Enters Into An Agreement With National Cancer Institute 113

Amsterdam Molecular Enters Into Cooperative Research and Development Agreement With National Institutes of Health 114

New Zealand Pharma Enters Into Co-Development Agreement With National Human Genome Research Institute For DEX-M74 115

RRD International Enters Into Co-Development Agreement With National Institutes of Health Therapeutics For Rare And Neglected Diseases 116

Selecta Biosciences Enters into Licensing Agreement with National Cancer Institute 117

NICHD Enters into Licensing Agreement with Cyprium Therapeutics 118

PaxVax Enters into Licensing Agreement with National Institutes of Health 119

ConverGene Enters into Licensing Agreement with National Center for Advancing Translational Sciences 120

Great Lakes Neuroscience Enters into Licensing Agreement with National Institutes of Health 120

Genesis Biopharma Enters Into Patent Licensing Agreement With National Institutes Of Health 121

Biologics Resources Enters into Licensing Agreement with National Institutes of Health 122

Medigen Vaccine Biologics Enters into Licensing Agreement with National Institutes of Health for Dengue Vaccine 123

Opiant Pharma Enters into Licensing Agreement with Walter Reed Army Institute of Research and National Institute on Drug Abuse 124

Kite Pharma Enters into Licensing Agreement with National Institutes of Health 125

Kite Pharma Enters into Licensing Agreement with National Institutes of Health 125

Butantan Institute Enters into Licensing Agreement with National Institute of Allergy and Infectious Diseases 126

Kite Pharma Enters into Licensing Agreement with National Institutes of Health 127

Lion Biotech Enters into Licensing Agreement with National Institutes of Health 128

Vtesse Enters into Licensing Agreement with National Institutes of Health for Cyclodextrins 129

Kite Pharma Enters into Licensing Agreement with National Institutes of Health for T Cell Receptor-Based Products 129

Exxell BIO Enters into Licensing Agreement with National Institute of Allergy and Infectious Diseases 131

Peptron Enters into Licensing agreement with National Institutes of Health 131

KannaLife Sciences Enters Into Licensing Agreement With NIH 132

Organic Vaccines Enters into Licensing Agreement with National Institutes of Health 133

Kite Pharma Enters into Licensing Agreement with National Institutes of Health for T Cell Receptor-Based Products 133

Aspyrian Therapeutics Enters Into Licensing Agreement With National Cancer Institute For Near-Infrared Photoimmunotherapy 134

Polyplus-transfection Enters into Licensing Agreeement with NIAID and NCI 135

Bavarian Nordic Enters into Licensing Agreement with National Institutes of Health 136

Radiation Control Technologies Enters Into Licensing Agreement With National Institutes of Health 137

NIH Center for Regenerative Medicine Enters Into Licensing Agreement With Horizon Discovery For Genesis Technology 137

KannaLife Sciences Enters Into Licensing Agreement With NIH-OTT 138

BioDigitalValley Enters Into Licensing Agreement With National Library of Medicine 139

BN ImmunoTherapeutics Enters Into Licensing Agreement With National Institutes of Health 139

Amsterdam Molecular Expands Licensing Agreement With National Institutes Of Health 141

NanoBio Enters Into Licensing Agreement With National Institutes Of Health 141

Ariadne Genomics Extends Licensing Agreement With NCI For Pathway Studio 142

National Institutes of Health, Key Competitors 144

National Institutes of Health, Key Employees 145

National Institutes of Health, Subsidiaries 146

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

National Institutes of Health, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license

Single User License
USD 250 INR 16088
Site License
USD 500 INR 32175
Corporate User License
USD 750 INR 48263

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com